<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476853</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 033</org_study_id>
    <nct_id>NCT00476853</nct_id>
  </id_info>
  <brief_title>Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy</brief_title>
  <official_title>A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>other sponsors:Japanese MOPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Labor and Welfare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thai MOPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thai GPO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Rai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central General Chest Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Institute of Tuberculosis (Japan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and&#xD;
      tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1&#xD;
      infected patients started at 2-6 weeks after initiating rifampicin containing&#xD;
      antituberculosis therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data from the HIVNAT PK laboratory indicate that out of 5/60 patients treated&#xD;
      with nevirapine (200 mg bid) and rifampicin had sub-therapeutic nevirapine levels (&lt;3.0 mg&#xD;
      mg/L). In a control group of 38 patients using nevirapine without rifampicin there were no&#xD;
      sub-therapeutic levels. A dose increase of nevirapine while patients who are receiving that&#xD;
      rifampicin may be required. Both nevirapine and rifampicin are tepatotoxic agents as are&#xD;
      other agents used in treatment of HIV or tuberculosis. Using a higher nevirapine may prevent&#xD;
      the occurrence of sub-therapeutic nevirapine levels, but may also induce more liver toxicity.&#xD;
      To address these issues, we designed a randomized prospective study to evaluate the safety,&#xD;
      efficacy and pharmacokinetics of nevirapine 400 mg/day versus 600 mg/day with a two weeks&#xD;
      lead-in 200 mg/day and 400 mg/day respectively, in TB-HIV co-infected patients who taking&#xD;
      rifampicin and short-term efficacy and toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of nevirapine based HAART 400 mg/day versus 600 mg/day on HIV-1 load as measured by HIV-1 RNA quantification in plasma</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of nevirapine based HAART 400 mg/day versus 600 mg/day</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nevirapine level at week 2, 4 and 12 and 12 hour PK at week 4 (only 20 patients)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune recovery syndrome, adherence, clinical improvement, incidence of new/recurrent AIDS events (CDC class C) between two group</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mortality or new/recurrent AIDS events (CDC class C), 1 year mortality rate of TB/HIV patients, emerging of ARV resistant especially nevirapine, emerging of anti-TB resistance</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP 600 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART containing nevirapine</intervention_name>
    <description>Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed HIV positive after voluntary counseling and testing&#xD;
&#xD;
          2. Aged 18-60 years of age&#xD;
&#xD;
          3. Antiretroviral treatment na√Øve.&#xD;
&#xD;
          4. CD4+ cell count of &lt; 200 cells/mm3 at the time of diagnosed TB&#xD;
&#xD;
          5. TB is diagnosed and using treatment with rifampin base therapy for at least 2 weeks&#xD;
             but no longer than 4 weeks duration. The requirement for study entry is at least one&#xD;
             acid-fast bacillus (AFB) positive smear with a typical syndrome and/or CXR findings&#xD;
             consistent with pulmonary TB. Pulmonary TB and / or extra pulmonary TB will be&#xD;
             included if AFB or culture for TB is positive.&#xD;
&#xD;
          6. No other active OI (CDC class C event)&#xD;
&#xD;
          7. Negative pregnancy test in females, and willing to use reliable contraception&#xD;
&#xD;
          8. Able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The following laboratory variables, i. absolute neutrophil count (ANC) &lt; 1000 cells/uL&#xD;
             ii. hemoglobin &lt; 6.5 g/dL iii. platelet count &lt; 50,000 cells/uL iv. serum AST, ALT &gt; 5&#xD;
             x ULN vi. serum bilirubin &gt; 2 x ULN vii. serum creatinine &gt; 2 x ULN viii. Pregnant or&#xD;
             nursing mothers.&#xD;
&#xD;
          2. Current use of steroid and other immunosuppressive agents.&#xD;
&#xD;
          3. Current use of any prohibited medications related to compliance and drug&#xD;
             pharmacokinetics (see appendix )&#xD;
&#xD;
          4. Acute therapy for serious infection or other serious medical illness (in the judgment&#xD;
             of the site Principal Investigator) requiring systemic treatment and/or&#xD;
             hospitalization.&#xD;
&#xD;
          5. Patients with current alcohol or illicit substance use that in the opinion of the site&#xD;
             Principal Investigator would conflict with any aspect of the conduct of the trial.&#xD;
&#xD;
          6. The persons who had been received a mono-therapy of nevirapine&#xD;
&#xD;
          7. Unlikely to be able to remain in follow-up for the protocol defined period.&#xD;
&#xD;
          8. Patients with chronic active liver disease.&#xD;
&#xD;
          9. Patients with proven or suspected acute hepatitis. Patients with chronic viral&#xD;
             hepatitis are eligible provided ALT, AST &lt; 5 x ULN.&#xD;
&#xD;
         10. Karnofsky performance score &lt;30%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Chest Hospital</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-TB</keyword>
  <keyword>nevirapine based HAART with rifampin treated TB</keyword>
  <keyword>Compare PK profile, efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus 600 mg/day in HIV/TB co-infected patients</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

